Tenaya Therapeutics Inc (NASDAQ: TNYA)’s stock price has plunge by -0.73relation to previous closing price of 0.45. Nevertheless, the company has seen a -11.02% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-31 that TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase Over Time All Cohort 1 Patients with Severe Disease at Baseline Achieved NYHA Class I Two of Three Patients Experienced Improvements in One or More Measures of Hypertrophy Expects to Complete Enrollment of Cohort 2 in 1H25 and to Report Initial Data in 2H25 SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced that interim data from the first three patients enrolled in the company’s MyPEAK-1 Phase 1b/2 clinical trial of TN-201 were highlighted in a Late-Breaker presentation at the 2025 American College of Cardiology Scientific Sessions (ACC.25).
Is It Worth Investing in Tenaya Therapeutics Inc (NASDAQ: TNYA) Right Now?
Moreover, the 36-month beta value for TNYA is 2.98. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TNYA is 134.13M and currently, short sellers hold a 8.07% of that float. On April 24, 2025, TNYA’s average trading volume was 3.35M shares.
TNYA’s Market Performance
The stock of Tenaya Therapeutics Inc (TNYA) has seen a -11.02% decrease in the past week, with a -35.50% drop in the past month, and a -64.73% fall in the past quarter. The volatility ratio for the week is 7.26%, and the volatility levels for the past 30 days are at 11.54% for TNYA. The simple moving average for the last 20 days is -11.73% for TNYA stock, with a simple moving average of -76.16% for the last 200 days.
Analysts’ Opinion of TNYA
Leerink Partners, on the other hand, stated in their research note that they expect to see TNYA reach a price target of $7. The rating they have provided for TNYA stocks is “Outperform” according to the report published on November 30th, 2023.
H.C. Wainwright gave a rating of “Buy” to TNYA, setting the target price at $25 in the report published on June 15th of the previous year.
TNYA Trading at -34.35% from the 50-Day Moving Average
After a stumble in the market that brought TNYA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.90% of loss for the given period.
Volatility was left at 11.54%, however, over the last 30 days, the volatility rate increased by 7.26%, as shares sank -30.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.67% lower at present.
During the last 5 trading sessions, TNYA fell by -11.02%, which changed the moving average for the period of 200-days by -84.54% in comparison to the 20-day moving average, which settled at $0.5115. In addition, Tenaya Therapeutics Inc saw -68.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TNYA starting from Higa Tomohiro, who sale 2,482 shares at the price of $0.54 back on Mar 10 ’25. After this action, Higa Tomohiro now owns 99,690 shares of Tenaya Therapeutics Inc, valued at $1,336 using the latest closing price.
Tingley Whittemore, the Chief Medical Officer of Tenaya Therapeutics Inc, sale 7,398 shares at $0.54 during a trade that took place back on Mar 10 ’25, which means that Tingley Whittemore is holding 174,793 shares at $3,983 based on the most recent closing price.
Stock Fundamentals for TNYA
The total capital return value is set at -1.12. Equity return is now at value -95.69, with -75.64 for asset returns.
Based on Tenaya Therapeutics Inc (TNYA), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -6.65.
Currently, EBITDA for the company is -115.95 million with net debt to EBITDA at -0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.22.
Conclusion
To wrap up, the performance of Tenaya Therapeutics Inc (TNYA) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
